Two-Year Treatment of Alzheimer’s Disease with Eptastigmine

Publisher： Karger

E-ISSN： 1421-9824|10|2|139-147

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.10, Iss.2, 1999-02, pp. : 139-147

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Prevalence of Neuropsychiatric Symptoms in Young-Onset Compared to Late-Onset Alzheimer’s Disease – Part 1: Findings of the Two-Year Longitudinal NeedYD-Study

By  

Dementia and Geriatric Cognitive Disorders, Vol. 34, Iss. 5-6, 2012-12 ,pp. : 319-327

Karger

Access to resources Recommend Favorite

A 6-Month, Double-Blind, Placebo-Controlled Trial of Eptastigmine in Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 11, Iss. 1, 2000-01 ,pp. : 17-24

Karger

Access to resources Recommend Favorite

Treatment of Alzheimer’s Disease with Clioquinol

By  

Dementia and Geriatric Cognitive Disorders, Vol. 12, Iss. 6, 2001-10 ,pp. : 408-414

Karger

Access to resources Recommend Favorite

Rivastigmine in the Treatment of Alzheimer’s Disease

By  

European Neurology, Vol. 46, Iss. 2, 2001-08 ,pp. : 110-110

Karger

Access to resources Recommend Favorite

Treatment of a Whole Population Sample of Alzheimer’s Disease with Donepezil over a 4-Year Period: Lessons Learned

By  

Dementia and Geriatric Cognitive Disorders, Vol. 25, Iss. 3, 2008-01 ,pp. : 226-231

Karger

Access to resources Recommend Favorite